Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This change, driven primarily by improvements in price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks.

A sharp decline over the past two sessions has dragged Sandu Pharmaceuticals Ltd to a fresh 52-week low of Rs 30 on 30 Mar 2026, marking a significant 49% drop from its peak of Rs 58.8 within the last year. This downturn comes despite some pockets of financial improvement, highlighting a complex interplay of market sentiment and company fundamentals.

Sandu Pharmaceuticals Ltd has seen its valuation parameters adjust from attractive to fair, reflecting a nuanced shift in investor sentiment amid a challenging market backdrop. Despite a recent downgrade to a Strong Sell rating, the company’s price-to-earnings and price-to-book ratios suggest a more balanced valuation compared to its historical averages and peer group, signalling a complex investment case for stakeholders.

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, warrants a detailed analysis to understand its implications for investors amid a challenging market backdrop.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed below reflect the stock's current position as of 19 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Sandu Pharmaceuticals Ltd has reached a new 52-week low of Rs.35.11, marking a significant decline amid broader market pressures and company-specific performance issues. The stock has underperformed its sector and benchmark indices, reflecting ongoing challenges in growth and profitability metrics.

Sandu Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.35.8 on 21 Jan 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and market performance.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 26 December 2025, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.36.76, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharma., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. This shift follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, underscoring the complexities faced by the stock in recent periods.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid broader market activity. The stock’s performance contrasts with the overall positive trend in the Sensex, highlighting ongoing challenges within the company’s financial and operational metrics.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.01 today, marking a significant decline in its stock price amid ongoing challenges in its financial performance and market positioning within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals touched a fresh 52-week low of Rs.37.21 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past three consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Sandu Pharmaceuticals has reached a new 52-week low of Rs.37.21 today, marking a significant decline amid broader market fluctuations and sector underperformance. The stock has experienced a notable downward trend over the past three days, reflecting ongoing challenges within the Pharmaceuticals & Biotechnology sector.